ArticleCell reports. Medicine2026
Design of a bispecific peptide-nanozyme conjugate for cancer immunotherapy.
Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lactate-Induced Liquid-Liquid Phase Separation of HIF-1α Drives Myeloid Cell Polarization and Immune Evasion in Colorectal Cancer.Cell proliferation · 2026Article
- Berberine induces PD-L1 degradation via the autophagy-lysosome pathway through the PI3K-Akt pathway and enhances immunogenic cell death in triple-negative breast cancer.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in cancer immunotherapy, clinical efficacy remains constrained by immunosuppressive tumor microenvironment (TME), including PD-L1-mediated T cell dysfunction and CXCL8-driven myeloid cell recruitment. To address this, a bispecific peptide-nanozyme conjugate (BsPNEC) is engineered. Leveraging iterative structure-guided optimization, we first develop q6w, a proteolysis-resistant D-peptide targeting CXCR1/2, and conjugate it to a PD-L1-blocking peptide to generate a bispecific peptide qGA. To augment the therapeutic efficacy, qGA is conjugated to Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.